Here are the top 5 articles detailing the advancements in hematologic oncology from 2025. BTK inhibitors have revolutionized treatment for hematologic malignancies, butacquired BTK mutations often ...
Covalent Bruton tyrosine kinase inhibitors (BTKis) have improved CLL management, but discontinuation due to adverse events ...
Kura Oncology, Inc. (NASDAQ:KURA) is one of the stocks Jim Cramer offered insights on. When a caller highlighted the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback